Title: Zaccara G, et al. Antiepileptic Drugs in Clinical Development: Differentiate or Die? Curr Pharm Des. 2017;23(37):5593-5605.
1835705-53-7 | PROTAC Linker 1 | AA01EO51 | MFCD31692348
863513-93-3 | Cebranopadol ((1α,4α)stereoisomer) | AA01EO9J | MFCD28386279
1415390-47-4 | (R)-BPO-27 | AA01EOFV | MFCD30532675
1370046-40-4 | SSE15206 | AA01EOLP | MFCD31746881
1394157-34-6 | Sofosbuvir impurity N | AA01EOPY | MFCD28386721
286834-86-4 | α-methyl-7-benzofuranethanamine,monohydrochloride | AA01EOZ2
958293-77-1 | 6-methoxy-α-(methyl-d3)-2-naphthaleneaceticacid | AA01EPAA | MFCD09841073
1400742-48-4 | 1-[(tetrahydro-2H-pyran-4-yl)methyl]-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide | AA01EPHT
104071-84-3 | 5,14-dioxo-9,10-dithia-2,6,13,17-tetraazaoctadecanedioicacid,1,18-bis(phenylmethyl)ester | AA01EPN0
1987882-62-1 | (2S)-25-cyclohexyl-5-O-demethyl-25-de(1-methylpropyl)-avermectinA1a | AA01EPTN